Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Österreich)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 87.41 USD | -6.67% |
|
-10.35% | -12.11% |
| Feb. 09 | US Equity Markets Close Mixed Friday, S&P Surpasses 5,000 Level | MT |
| Feb. 09 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
Financials (USD)
| Sales 2023 * | 6.54B | Sales 2024 * | 4.4B | Capitalization | 33.33B |
|---|---|---|---|---|---|
| Net income 2023 * | -5.28B | Net income 2024 * | -2.46B | EV / Sales 2023 * | 4.24 x |
| Net cash position 2023 * | 5.57B | Net cash position 2024 * | 3.6B | EV / Sales 2024 * | 6.76 x |
| P/E ratio 2023 * |
-6.46
x | P/E ratio 2024 * |
-13.6
x | Employees | 3,900 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 90.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Moderna, Inc.
More recommendations
More press releases
More news
| 1 day | -6.67% | ||
| 1 week | -10.35% | ||
| Current month | -13.50% | ||
| 1 month | -20.67% | ||
| 3 months | +25.75% | ||
| 6 months | -14.15% | ||
| Current year | -12.11% |
1 week
86.41
100.24
1 month
86.41110.80
Current year
86.41115.97
1 year
62.55177.37
3 years
62.55497.49
5 years
11.54497.49
10 years
11.54497.49
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 51 | 11-02-28 |
Stephen Hoge
PSD | President | 48 | 12-12-31 |
James Mock
DFI | Director of Finance/CFO | 47 | 22-09-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 65 | 18-05-31 |
| Director/Board Member | 74 | 20-06-30 | |
Francois Nader
BRD | Director/Board Member | 67 | 19-12-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.66% | 0 M€ | 0.00% | - | |
| 4.69% | 2 M€ | -.--% | ||
| 4.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-02-09 | 87.41 | -6.67% | 7,216,450 |
| 24-02-08 | 93.66 | -5.68% | 4,916,430 |
| 24-02-07 | 99.3 | -0.73% | 2,271,473 |
| 24-02-06 | 100 | +4.75% | 3,046,850 |
| 24-02-05 | 95.49 | -2.06% | 2,799,244 |
Delayed Quote Nasdaq, February 09, 2024 at 04:00 pm EST
More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2024-02-22
- Q4 2023 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
87.41
USD
Average target price
133.8
USD
Spread / Average Target
+53.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.11% | 33 328 M $ | |
| -5.70% | 39 822 M $ | |
| +25.64% | 37 738 M $ | |
| -10.87% | 28 365 M $ | |
| -1.62% | 22 926 M $ | |
| -11.17% | 21 338 M $ | |
| -6.00% | 11 399 M $ | |
| -11.94% | 10 681 M $ | |
| +6.48% | 10 015 M $ | |
| -3.43% | 9 979 M $ |
